A moderate dose of quinine sulfate, administered to three young adult males, reduced or eliminated various forms of otoacoustic emission (OAE). The individual differences in response to the drug were substantial, but a number of generalizations did emerge. The time courses of onset and recovery were considerably more rapid than for the parallel effects produced by aspirin. Most spontaneous otoacoustic emissions (SOAEs) were eliminated within 7 h of the first 325-mg dose (about 3 h after the second dose). Most $OAEs showed partial or complete recovery about 24 h after the last dose, although considerable instability often remained. The functions relating the magnitude of a distortion-product OAE (DPOAE) to the sound-pressure level (SPL) of the primary tones producing it were displaced toward higher primary levels and became lower sloped following quinine administration. The magnitudes of $OAEs, DPOAEs, and nonlinear peaks in the click-evoked spectra declined and recovered with grossly similar time courses, but there were some partial dissociations. The ability of a DPOAE to suppress an $OAE lying about 50 Hz below it either increased slightly or remained about constant through the drug episode, even though the magnitudes of both DPOAE and $OAE were changing. On several occasions, increases in SOAE magnitude of as much as 10-20 dB were observed during the first 15-30 min of an SOAE measurement period (an initializing effect). Psychophysical measures revealed hearing losses of as much as 20 dB at some frequencies in some subjects. Several short-lived "enhancements" of OAEs are discussed relative to similar quinine-induced effects reported in an animal model.
INTRODUCTION
The ototoxic potential of quinine compounds has been recognized for at least three hundred years (see review by Hawkins, 1976) . Typical symptoms include hearing loss and tinnitus, both of which are generally totally eliminated within 24-72 h of cessation of the drug--unless high doses or protracted administration were necessary. While a number of possible mechanisms of action have been proposed for quinine's ability to produce hearing loss and tinnitus (see Karlsson et al., 199 lb; Jastreboff et al., 1991 ) , none is universally accepted.
Several recent reports strongly suggest that quinine can act directly at peripheral auditory sites. Karlsson et al. ( 199 lb) reported that the administration of quinine could increase the amplitude of vibration of the cochlear partition in their in vitro preparation of the cochlea. Karlsson and Flock (1990) demonstrated that quinine can alter the slow motile response of isolated cochlear outer hair cells, which raises the prospect that it might also affect the socalled active cochlear process or cochlear amplifier (Davis, 1983 ). Stypulkowski and Oriaku ( 1991 ) made a number of physiological measurements on chinchillas comparing the effects of quinine and salicylate, two drugs that affect the permeability of cell membranes in different ways, but which can produce similar losses in hearing (Puel et 
A. Subjects
The subjects were three males, aged 24 to 35 years. All had hearing better than 15 dB HL at audiometric test frequencies ranging from 500-6000 Hz, as measured with an adjustment technique (Rudmose ARJ4A audiometer). The subjects were given a physical exam, including blood and urine tests, designed to identify any contraindications to the administration of quinine sulfate. Consent forms informed the subjects of the various risks and side effects commonly associated with quinine use (see Webster, measurements were made with the subject lying on a camp cot in an electrically shielded, sound-proofed room having an intercom that allowed two-way communication. Emissions were monitored using an Etymotic ER-10 low-noise microphone system inserted into the outer ear canal. This system consists of a recording microphone plus two polyvinyl sound-delivery tubes, each of which was attached to an ER-2 insert earphone. The output of the recording microphone was led to an Etymotic ER10-72 preamplifier and then passed through a low-noise amplifier/filter combination that provided about 30 dB of gain and high passed the microphone output at 400 Hz. The output of this amplifier/filter was led to a Nicolet/Wavetek 444a MiniUbiquitous spectrum analyzer located outside the soundproofed room. For SOAEs and DPOAEs, the spectrum analyzer was set to sum eight "samples" (fast Fourier transforms) for each measurement. Emission magnitudes were read directly from the screen of the spectrum analyzer in units of dB re: 1 V, which were later transformed into dB SPL (re: 20/zPa). All SOAE and DPOAE measurements reported here were obtained with the spectrum analyzer set to its frequency-expansion mode, meaning that frequency resolution was in steps of 0.25 Hz. • Estimates of the noise level in the local vicinity of each emission were regularly noted and found to be quite stable. Ideally, these noise levels would correspond to the noise floor imposed by the electronics used, but in practice they are invariably determined by the ambient body noise generated by the individual subject. Baseline measurements of SOAEs, DPOAEs, and TEOAEs were obtained in the nondrug state for later comparison with data collected during drug administration. The frequency and level of the SOAEs were monitored on a number of occasions in the nondrug state, both before and after the drug episodes. Pre-drug baseline SOAE measurements were collected only after the subject had reclined on the cot, with the emissions-recording equipment in place, for at least 15 rain (Whitehead, 1991) .
For the study of DPOAEs, a pair of primary tones having an f2/f• ratio of 1.15 was chosen for each subject individually such that the 2f•--f2 distortion product lay about 50 Hz above a strong SOAE. With this arrangement, suppression effects of the DPOAE on the SOAE could easily be observed at the same time the magnitude of the DPOAE produced by a particular level of the primaries was being determined.
• The primary tones were obtained from two General Radio 1310A oscillators. The primaries were always presented via separate transducers, and were adjusted to be equal in level in the individual ear canals using the microphone in the probe assembly. The maximum level used for the primaries in these measurements was 54 dB SPL in order to stay below the point at which the spectrum analyzer began to show inherent distortion at the 2f•--f• frequency.
For the transient-evoked OAEs, unfiltered condensation clicks of 100-/zs duration were presented at a maximum rate of 2 per second, and the responses were averaged as follows. Beginning 4 ms after click offset, a 40-ms sample of the microphone response ( 1024 points collected at a sampling frequency of 25.6 kHz) was collected using the Nicolet/Wavetek analyzer. This sample was retained in the time domain, and, immediately upon collection, was delivered to a PDP 11/73 computer for summing with previously collected samples. The "averaged" waveform based upon 50 such time samples was ultimately converted to 16-bit digital format and saved as a computer file on which further analysis was performed. The 11/73 computer also generated the click stimuli and controlled the timing of their presentation. The levels of the click stimulus are specified here as the SPL of a 1000-Hz tone whose maximum amplitude corresponded to the magnitude of the 100-/zs electrical pulse at the output of the miniature microphone (in a 2-cc coupler) when both waveforms were displayed on a storage oscilloscope. Typically, data were collected for several levels of the click in rapid succession. Before each TEOAE (and DPOAE) measurement session, the level of the stimulus was set using the output of the microphone system, with the subject in place. The level of the clicks ranged from about 37 to 49 dB corresponding peak SPL, which equaled about 2-to 14-dB sensation level (SL) for subject CW.
Several procedures were implemented to reduce the noise level in the click-evoked time samples collected. First, the output of the microphone system was checked by the 11/73 computer just before the presentation of each scheduled click, and if the noise level was not below 25 dB SPL overall (from 0-10 kHz), the presentation of the click was postponed until it was. Thus, if a subject were extremely quiet, all of the clicks would, in fact, be presented at a rate of 2 per second, but, more typically, the subjects' body movements and other noises caused the click presentations to be somewhat irregular. (By listening to the click sequence, the subject could determine when he was being sufficiently quiet.) Second, only the last 50 of 54 click presentations were used to produce the averaged response to the click. Third, although the bandwidth of the time samples was 10 kHz, only spectral components below 3 kHz were considered. Finally, only 20 ms of the averaged waveform was subjected to spectral analysis, and that segment began 5 ms into the computer file (i.e., beginning 9 ms following click presentation).
The pre-drug baseline measurements also included psychophysical determinations of sensitivity in the quiet for test frequencies covering the range from 250-6000 Hz. The psychophysical procedure used was adaptive, twointerval forced-choice with feedback. The three-down/ one-up rule was used to track the 79% point on the psychometric function (Levitt, 1971 ). The signal level was initially adjusted in 4-dB steps, becoming 2-dB steps after the second reversal. Block length was 60 trials, signal duration was 200 ms (including 10-ms rise and decay times), and the headphones were TDH-39s mounted in circumaural cushions. The trial-timing sequence was warning interval and light ( 100 ms), pause (500 ms), first observation interval and light (200 ms), pause (500 ms), second observation interval and light (200 ms), response interval (1000 ms), and feedback interval and light (300 ms).
C. Dose schedule
The quinine sulfate was administered in standard tablets of 325 mg taken at the approximate rate of 1 every 4 h, in the experimenters' presence. Subject MP took three doses total, and subject LB took two doses total. For subject CW [who is not the CW who served in Wier et al. (1988) ], two drug runs were conducted. During pass 1, CW's daily dose schedule was one tablet at 12:00 noon, 4:00 p.m., 8:00 p.m., 12:00 midnight, and 8:00 a.m., which corresponded to 1.625 g per 24-h period. During pass 2, CW took only two doses, also separated by 4 h and beginning at noon. Twenty-one days separated the two passes. For subjects MP and LB, the first dose was at 9:00 a.m. Each 325-mg tablet corresponded to about 4.4, 4.2, and 4.6 mg/kg for subjects MP, LB, and CW, respectively.
II. RESULTS

A. SOAE results
Decline and recovery of SOAEs
First, we will consider the effects of quinine on SOAEs. In the SOAE figures presented here, the levels of the emissions are expressed in decibels above the average noise floor of our recording system at the frequency of that emission and with the subject in place. These ordinate values can be converted back into SPL by using the correction factors provided in the captions of Figs. 1-4.
In Fig. 1 In Fig. 2 are shown the SOAE results for subject LB, who had two emissions. For this subject, there was evidence of a decline in both SOAEs within about 2 h of the first dose, and, just as for subject MP, the emissions were absent beginning about the hour-6 mark. For the stronger, 1895-Hz emission, recovery was apparently complete about 25 h after the first dose, and recovery was also beginning at that time for the weaker, 1420-Hz emission. This faster recovery for LB than for MP is presumably attributable in part to the fact that LB had only two doses of the quinine sulfate and MP had three. While the two schedule, in part, on the basis of our experience with aspirin, which, we now know, acts much more slowly than quinine.) For this and other reasons that will become obvious, the data from these two passes will be presented separately. Figure 3 shows the SOAE data from pass 1 for subject CW. This subject had four emissions of varying strengths, and on pass 1 he received a total of five doses of quinine sulfate. By 3 h after the first dose, two SOAEs (1070 and 2015 Hz) were already substantially reduced in level--although the 1070-Hz emission later rebounded toward its normal value as the other emissions were further reduced. During pass 2, which began 21 days after the last dose of pass 1, the onset of effect was not as rapid as during pass 1. We believe that this difference is attributable in large part to the fact that on pass 1 the first dose was taken at noon and no food was consumed for about an hour, while on pass 2 the first dose was taken about an hour after a large breakfast. Presumably, absorption of the drug was retarded in the latter case, explaining the slower time course of decline in the SOAEs. Figure 4 shows that, during pass 2, there was little change in any emission until A short-lived quasi-stable state. At about 4 h after the second dose in CW's pass 2, his sole remaining SOAE began to alternate between two specific frequencies--1565 and 1495 Hz. Initially, the jumps from one frequency to the other were "spontaneous" in the sense that they occurred in the absence of anything we, or the subject, were (aware of) doing to initiate them. The emission would jump to 1495 Hz and dwell there for anywhere from 5-120 s before returning to 1565 Hz, behavior that is reminiscent of the quasi-stable-state behavior reported by Burns et al. (1984) . The return to 1565 Hz was often accompanied by a large body-noise artifact on the spectrum analyzer. The level of the SOAE was about 12 dB SPL irrespective of which frequency was evident. During this time, we noticed that the emission often jumped to 1495 Hz when we spoke to the subject over the intercom, so we tried whispering in his contralateral ear, which also produced jumps for a time. Attempts to obtain more objective information about this unusual effect were not particularly successful. At first, when tones several hundred Hertz lower in frequency than the emission were presented to the contralateral ear using an ER-10 earphone, a jump in the emission to 1495 Hz could be reliably obtained, but not when the contralateral tone was similar to, or above, the frequency of the emission. However, attempts to replicate this respectively. No such episodes have ever been observed in subject CW, whose emissions we have studied on numerous occasions over the course of many months, with and without drugs. (To avoid possible confusions between initializing effects and drug effects, only the final point or two in each of these initializing runs was plotted in Figs. 1 and 2 for these two subjects.)
The initializing episodes around hours 3 and 128 for subject LB reveal that the levels of multiple emissions in the same ear may not fluctuate in a correlated manner, a fact that will have to be addressed by any proposed explanation of the initializing effect. During the initializing periods, the SOAEs of MP and LB changed only very slightly in frequency (typically downward by less than 0.2% ).3
B. DPOAE results
By positioning the 2fl-f2 distortion product about 50 Hz above an SOAE, both an input/output function for the DPOAE and a suppression function for the SOAE could be determined concurrently as the common level of the primaries was varied. The DPOAE data will be discussed in this section and SOAE suppression in the next. 4
For all three subjects, the general effect of quinine was to displace the DPOAE input/output functions toward successively higher primary levels and to successively re- DPOAEs were --3 dB SPL, they were about 43, 40, and 36 dB down from the primaries for subjects MP, LB, and CW, respectively. As can be seen from the top panel of Fig. 7 , for subject MP, the DPOAE input/output function was shifted by about 4 dB toward higher primary levels about 2.7 h after the first dose. Then, beginning about 6.8 h after his first dose, his DPOAE could not be detected, and this remained true until 33.3 (25.3) h after the first (last) dose. Recovery was not complete until about 78 (70) h after the first (last) dose for this subject (see top panel of Fig. 10) . Thus, for subject MP, the time courses of decline and recovery were similar for SOAE and DPOAE (compare Figs. 1 and 10) .
The DPOAE input/output functions of subject CW, like his SOAEs, behaved somewhat differently during his two drug episodes. Another difficulty was that the no-drug input/output function measured just prior to pass 2 was shifted slightly toward weaker primary levels from the function measured just prior to pass 1 (determined about 12 days earlier). In ignorance of the basis for this shift, it seemed prudent to use as the pre-drug baseline, the function determined closest in time to each drug episode. Accordingly, different "pre-drug" functions appear in the two top panels of Fig. 8. During pass 1 [Fig. 8 (a) Fig. 11 ).
increases in suppression. In the pre-drug condition for CW (pass 1), suppression increased by about 8 dB for each 1 dB of increase in the primaries; this fell to about 1.4 dB/1 dB at 3 h after the first dose. For MP, the corresponding numbers were about 5.8 dB/1 dB (pre-drug) and 1.5 dB/1 dB (at hour 33), and for LB, they were about 2.7 dB/1 dB (pre-drug) and subjects, the general shape of the suppression functions did clearly change following administration of quinine; they were displaced somewhat to the right and became somewhat lower sloped. In addition, for MP, the curves were displaced downward considerably (as the SOAE lost magnitude), an effect that was much smaller for subjects LB and CW. In part, this difference is attributable to the times in the drug episodes when suppression measurements were made. For LB and CW, the suppression measurements were, perhaps unfortunately, taken at times when the SOAEs were either absent or undiminished by the drug. Note that at hour 45.6 of pass 1, CW's SOAE at 1580 Hz was essentially normal in level (Fig. 3) , and the DPOAE input/output function was only slightly displaced from the baseline [ Fig. 8 (a) ], yet the Suppression function was still markedly abnormal [ Fig. 8 (c) ]. In general, once the level of the primary tones (actually, the DPOAE) became high enough to initiate suppression, further small increases in the primaries led to large
Effectiveness of suppression
Because the magnitudes of the SOAEs and the DPOAEs were both changing, at different rates, following administration of quinine sulfate, it is difficult to determine by visual inspection of the suppression and input/output functions (bottom and top panels, respectively, of Figs. 7 and 8) whether, or how, the "effectiveness of suppression" was altered by the drug. In an attempt to resolve that problem, the following procedure was used. For each measurement period through the course of each drug episode, two values were noted for each setting of the primary tones--the level of the DPOAE produced and the level of the (suppressed) SOAE (top and bottom panels, respectively, of Figs. 7 and 8) . The latter values were subtracted from the average magnitude of the (unsuppressed) SOAE at that stage in the drug regimen in order to obtain an estimate of the amount of suppression being produced by the DPOAE. These estimates of SOAE suppression were used as ordinate values and plotted above the corresponding level of the DPOAE then produced by that level of the primaries. To the extent that the same amount of SOAE suppression is produced by the same magnitude of DPOAE at different points in the drug regimen, one could conclude that the effectiveness of suppression is unchanged by the drug and, further, that the DPOAE is the suppressor of the SOAE.
The results of this analysis of the effectiveness of suppression are shown in Fig. 9 for all three subjects. For MP, there was a tendency for the DPOAE to produce more suppression of the SOAE with the drug than without it. A similar effect could be seen for CW (both passes), at least for the data collected within about the first 6 h of the first dose. For subject LB, there was a clear appearance of greater suppression of the SOAE after the drug than before it, but that impression must be examined with care. Note that the most extreme data points for LB in Fig. 9 came from measurements obtained well into the recovery period. within its normal range at hours 26.8, 29.8, and 106.6 after the first dose, yet the most errant points in Fig. 9 come from the first two of those conditions. Said differently, LB's SOAE seemed to show greater-than-normal suppression as an aftereffect of exposure to the drug--an aftereffect that had not fully dissipated more than four days after the first dose.
When interpreting these data, it is necessary to keep two facts in mind. First, the frequencies of the SOAEs often drifted downward slightly following administration of the drug (see Sec. II A 2), meaning that the frequency separations between the SOAE and its DPOAE suppressor were not constant across all measurement periods shown in Figs. 7 and 8. Second, as the level of the primaries was increased (within a given measurement session), the frequency of the SOAE was invariably displaced even further downward; that is, there was a "repulsion" from the DPOAE frequency of as much as --0.7%. Presumably, these increased frequency separations contributed to slight reductions in the power of the DPOAE to suppress the SOAE. The increased frequency separations also reveal that the suppression reported here was not based on the entrainment observed by van Dijk and Wit (1988).
O. Click-evoked OAE results
The averaged click-evoked responses (see Sec. I B above) were analyzed spectrally using the computer pro Two of the present subjects did show some hearing loss at at least one test frequency within 6-8 h after the first dose. For subject MP [ Fig. 10(b) ], there were early losses at all test frequencies (except one) which peaked at 6-10 dB about 8 h after the first dose, and small hearing losses still remained at some frequencies 69 h after the last dose. For subject LB [ Fig. 11 (b) ], there were early improvements in hearing at some frequencies even though hearing at 6000 Hz was impaired by about 14 dB at hour 7. The subject taking the drug the longest [CW, pass 1; Fig.  12(b) ], also showed some early improvements in hearing at two frequencies, but hearing losses of about 2-20 dB then developed by hour 23.5 after the first dose (4 h after the fifth dose). On pass 2 (not shown), subject CW exhibited no early improvements in hearing, but did exhibit losses of up to 11 dB by hour 9 (4.75) after the first (last) dose. 5
While the temporal sampling of data makes it difficult to be certain, it appears from Figs. 10-12 that hearing loss did not occur until well after the distortion-product, clickevoked, and spontaneous emissions had begun to diminish, an outcome that may be attributable to the same mecha- 
F. Phenomenology
Most of the subjects were aware of transient elevations of pulse rate within a couple hours of the first dose of quinine sulfate, and all experienced short episodes of warm-feeling skin or a flushed face. Within a few hours of the first dose, two of the subjects mentioned having a bitter or metallic taste in their mouths, which disappeared within 24 h. Also, beginning about 6-7 h after the first dose, the subjects all reported a weak tinnitus that was variously described as "soft roaring" and "distant waterfall"; for subject MP, this tinnitus became more tonal before disappearing. At about this time, subject CW mentioned that some of our test tones sounded distorted or "hollow," and subject LB mentioned that the 200-ms tones used to test for hearing loss sounded as if they had a long reverberation time--"like the 'boing' of sonar pings." These latter effects were largely gone within about 24 h of the last dose. During recovery, two subjects reported hearing mid-or highpitched tinnitus at about the same time their SOAEs were returning, or new emissions were present, but time did not permit pursuing these possible correlations. (Fig. 3) ; and (4) new SOAEs emerged from the noise floor for CW (both passes).
However, while these examples are of some interest individually, they do not constitute evidence for a generalized enhancement because: ( 1 ) typically, concomitant effects were absent from the other measures obtained at about the same times in the drug episode, and in some cases, other measures were actually shifted in the opposite direction (dissociated); (2) for LB, heating sensitivity appeared heightened at different test frequencies at different points in the drug episode; (3) CW showed similar DPOAE "enhancements" at 73 h (pass 1) and 52.2 h (pass 2) after the first doses [ Fig. 8 (a) and (b) I--long after all quinine effects on SOAEs had dissipated (at least for pass 2); (4) given that noticeably different "baseline" DPOAE functions were obtained before passes 1 and 2 for CW, we are reluctant to argue for the existence of enhance- The failure to observe an obvious, generalized enhancement could be attributable to any of a number of factors, including individual differences, species differences, mode of drug administration, dose level, and fineness of temporal sampling. Another possibility is that the electrically evoked OAE studied by Stypulkowski and Oriaku (1991) simply behaves differently from other OAEs. Hubbard and Mountain (1990) suggested that the cochlear-amplification function performed by the outer hair cells actually consists of two processes--forward and reverse transduction--and that different ototoxic agents can differentially affect the two, and, thereby, differentially affect different types of OAE. According to this model, then, there is no necessary reason to expect to see enhancements in other OAEs just because there is an enhancement of the electrically evoked OAE. Note that between hours 3-5 of CW's pass 1, the level of the SOAE at 1070 Hz (Fig. 3, solid triangles) (Fig. 3) , and the DPOAE input/output function was only slightly displaced from the baseline [ Fig. 8(a) 
C. Sites of action
As noted in the Introduction, the findings of Karlsson and Flock (1990) and Stypulkowski and Oriaku ( 1991 ) suggest that quinine has the ability to affect the cochlear amplifier (CA) or active process (Davis, 1983) , which is widely regarded as involving the outer hair cells.
Stypulkowski and Oriaku ( 1991 ) compared the effects of quinine and salicylate in chinchillas and found that both drugs reduced the AP response and the spontaneous activity recorded with a round-window electrode. However, other effects went in opposite directions with the two drugs. For example, salicylate increased the cochlear microphonic, at least at low sound-pressure levels, whereas quinine decreased the cochlear microphonic across the full range of levels studied. As noted, the onset of effect was always faster for quinine than for salicylate. Puel et al. , 1988) . In general, the most effective suppressor is a tone or distortion product just above the frequency of the SOAE, but suppression grows more rapidly for suppressors on the low-frequency side of the SOAE than for those on the high-frequency side. Here, for all three subjects there was some evidence of greater suppression of the SOAE by the DPOAE at various times during or after the drug period (Fig. 9) Because the common level of the primary tones used here was always below 55 dB, only the low-level generator of distortion products was activated. The high-level generator seen in animal models (see Whitehead et al., 1992) , and the suppression it produces, also deserve study with quinine.
IV. SUMMARY
The main points of this paper are the following.
( 1 ) In addition to its previously known ability to produce hearing loss, quinine sulfate is capable of reducing or eliminating SOAEs, DPOAEs, and TEOAEs in humans.
(2) Quinine's effects on OAEs can be seen within a couple of hours of the first dose and they generally proceed much faster than the similar effects of aspirin. This suggests that quinine may be a better choice than aspirin when there is a desire to induce a reversible cochlear hearing loss in certain physiological preparations. This rapid onset of effects is in accord with the rapid physiological effects observed by Stypulkowski and Oriaku (1991) .
(3) Unlike certain physiological experiments, no convincing evidence was found for an enhancement of any OAE (see Sec. IIIA).
(4) SOAEs were greatly reduced or eliminated in all three subjects by about 6 h after the first dose, and it took 1-3 days after the last dose for the SOAEs to return to their normal levels. There was evidence of aftereffects lasting as long as 4 days (subject LB, Fig. 2 ). •Having such high-frequency resolution is an advantage for some purposes, but it raises a problem when trying to characterize the level of an SOAE. The reason is that many SOAEs appear as relatively broad regions of elevated level rather than as sharp spectral peaks. [It is yet to be determined whether this is because these SOAEs originate from truly narrow-band sources or from sources that are instantaneously sinusoidal but varying slightly in frequency across time, although a report by Rao and Bilger (1991) suggests the latter.] An experimenter desiring to obtain a precise measure of the overall level of such a broad-peaked SOAE would have to sum across this region of elevated frequencies, and across only those frequencies (which raises a difficult problem of definition). If individual labs are doing this, they are not describing the process in their published works. [Some experimenters may have attempted to circumvent the problem by making measurements with less-than-maximal frequency resolution, some have used the "improved accuracy" mode available on certain spectrum analyzers (G. R. Long, personal communication), and one lab has recently begun to use a curve-fitting procedure to solve the problem (Talmadge et al., 1993) .] From reading Methods sections of published papers, one must infer that the typical procedure is simply to take as the level of the emission the level in the most intense frequency bin (whatever its width in the measurement system being used) in the local frequency region of the spontaneous emission. That was the procedure used for the present experiment, meaning that our measures always underestimated the "overall levels" of SOAEs. Because a common reaction to a drug is for an. SOAE to increase in bandwidth as its level is reduced (also see Talmadge et al., 1993) , the measurements made following drug administration are more subject to underestimation than are the baseline measurements. Note that a druginduced change only in the variability of an SOAE's frequency during the measurement period would result in changes in the magnitude of the most intense bin, and thus, to under-or overestimates of its "true" "overall level" at that time. Clearly, comparisons of SOAE levels obtained in different laboratories and with different measurement systems must be made with great care. This general measurement problem also exists for DPOAEs, but to a much lesser extent because their energy is invariably concentrated in only one or two adjacent 0.25-Hz bins and is in a known frequency region. Note that the use of a relatively large frequency bin is not a panacea, for a number of reasons; most notably, the levels of highly narrow-band SOAEs will be overestimated, particularly for SOAEs that are just above the noise floor.
2As an anonymous reviewer has emphasized, the effects of quinine on the behavior of the DPOAE and on its suppression of the SOAE may have been complicated here by the proximity of the DPOAE to the SOAE. DPOAEs are known to be stronger when in the vicinity of an SOAE (see Probst et al., 1991 ) , and strong DPOAEs are thought capable of giving rise to a stimulus-frequency otoacoustic emission (SFOAE; see Probst et al., 1991 ) . To the extent that there was a strong SFOAE component in the DPOAE, and that it played a role in SOAE suppression in the pre-drug condition, there was the potential for quinine to alter suppression and DPOAE expression in a number of direct and indirect ways. For example, there may have been a drug effect on the mechanism(s) ( 1 ) producing the DPOAE, (2) producing the additional strength of the DPOAE, (3) producing the SFOAE at the DPOAE frequency, and/or (4) enabling the DPOAE to suppress the SOAE.
3Unfortunately, we have little information about the existence, or magnitude, of initializing effects in these two subjects obtained prior to the administration of quinine. The reason is that standard practice in this lab has long been not to collect emissions data until the subject has been allowed to lie quietly in the test room for at least 15 min after insertion of the probe tip. The large initializing effects shown in Figs. 5 and 6 were discovered when collecting data during the drug episodes, when it was important to obtain SOAE measurements as frequently as possible. What is available are data from test runs conducted several days after the final dose, and these suggest that the drug did magnify the initializing effect, at least for subject LB.
4Initializing effects had minimal impact on the DPOAE and TEOAE data because those conditions were typically not tested until after the subject had been lying in the test room for tens of minutes while SOAEs were being measured.
5In all cases but one, the hearing data shown were obtained from the ear 
